ReTARGETingALD: A precision HSC gene therapy for cerebral X-ALD

This research project aims to develop a new treatment for X-linked adrenoleukodystrophy (X-ALD), a severe brain disorder caused by genetic mutations. Current treatments, while promising, have limitations. The proposed approach uses advanced gene editing techniques to insert a healthy copy of the ABCD1 gene into specific cells of the patient’s own blood stem cells.

The researchers plan to use a method called CRISPR-Cas9 to precisely place the healthy gene in a way that could make the treatment more effective and safer than current gene therapy approaches. This technique is designed to produce long-lasting effects, while reducing the risks and limitations of currently available therapies.

The team will test this new approach in laboratory models, including 3D structures that mimic human brain tissue and in mice with X-ALD. They will also compare it to a more traditional gene therapy method as a backup strategy.

If successful, this innovative approach could overcome current limitations in X-ALD treatment and potentially serve as a model for treating other brain disorders. The project combines proven principles with cutting-edge technologies, aiming to translate scientific advancements into real-world medical treatments.